Submission+ at NYP

Application and Review Process
Interested applicants must submit a Letter of Intent (LOI) to the Dalio Center to be considered for the LHS and Health Justice Research and Training Award. The LOI is a short document outlining the proposed research, including the specific aims of the research and the research’s role in eliminating health inequities. See Appendix A for the LOI instructions.
The Dalio Center and EQUIP Center will review all LOIs and invite a subset of applicants to submit a full, long-form application for consideration. The Review Committee, composed of representatives of the Dalio Center and EQUIP Leadership, as well as faculty from both Weill Cornell Medicine and Columbia University, will review all long-form applications and select the final awardees. See Appendix B for the long-form application instructions.

Project Eligibility Criteria

All project proposals should:

• Clearly and directly address the intersection of health equity and/or health disparities with patient safety and quality research. Learn more about the intersection of health equity and quality here.
• Help inform a clear path toward sustained reduction in disparities in health outcomes (which could include system-level interventions across the health enterprise, rapid-cycle randomized trials, clinical decision support tools, community based participatory research, and more)
• Closely align with the mission and vision of the Dalio Center for Health Justice and EQUIP Center for LHS Science

Principal Investigator (“PI”) Criteria

• Appointed full-time faculty member of Weill Cornell Medicine or Columbia University at the time of application.
• MD, PhD, equivalent clinical professional degree, and/or clinical licensure
• During each application cycle, only one submission is permitted per principal investigator (PI). Principal investigators may be listed as co-investigators or consultants on other applications.
• Only one individual may be designated as principal investigator (i.e., no co-principal investigators).
• Preference will be given to applications that are enterprise-wide, with co-investigators from both Columbia University and Weill Cornell Medicine.

We encourage faculty who would benefit most from the additional program resources (e.g., New or Early-Stage Investigator (NI/ESI) and those who have not yet received a substantial funding award (R01 or equivalent)) to apply.

We strongly encourage applications from underrepresented groups.